WuXi Biologics (Cayman) Inc. Website

WuXi Biologics (Cayman) Inc.

SEHK-2269

Basic

  • Market Cap

    HK$48.74B

  • EV

    HK$45.44B

  • Shares Out

    4,151.46M

  • Revenue

    CN¥17.03B

  • Employees

    12,740

Margins

  • Gross

    40.08%

  • EBITDA

    28.93%

  • Operating

    23.09%

  • Pre-Tax

    24.5%

  • Net

    19.96%

  • FCF

    3.65%

Returns (5Yr Avg)

  • ROA

    8.01%

  • ROTA

    10.88%

  • ROE

    10.63%

  • ROCE

    8.85%

  • ROIC

    9.47%

Valuation (TTM)

  • P/E

  • P/B

  • EV/Sales

  • EV/EBITDA

  • P/FCF

  • EV/Gross Profit

Valuation (NTM)

  • Price Target

    HK$26.44

  • P/E

  • PEG

  • EV/Sales

  • EV/EBITDA

  • P/FCF

Financial Health

  • Cash

    CN¥11.24B

  • Net Debt

    -CN¥6,682.08M

  • Debt/Equity

    0.1

  • EBIT/Interest

    24.81

Growth (CAGR)

  • Rev 3Yr

    44.79%

  • Rev 5Yr

    46.38%

  • Rev 10Yr

  • Dil EPS 3Yr

    24.54%

  • Dil EPS 5Yr

    37.02%

  • Dil EPS 10Yr

  • Rev Fwd 2Yr

    12.45%

  • EBITDA Fwd 2Yr

    4.92%

  • EPS Fwd 2Yr

    6.58%

  • EPS LT Growth Est

    18.32%

Dividends

  • Yield

  • Payout

  • DPS

  • DPS Growth 3Yr

  • DPS Growth 5Yr

  • DPS Growth 10Yr

  • DPS Growth Fwd 2Yr

Select a metric from the list below to chart it

Dec '14

Dec '15

Dec '16

Dec '17

Dec '18

Dec '19

Dec '20

Dec '21

Dec '22

Dec '23

Dec '24 (E)

Dec '25 (E)

Dec '26 (E)

Total Revenues

3,983.7

5,612.4

10,290.1

15,268.7

17,034.3

Total Revenues % Chg.

57.2%

40.9%

83.3%

48.4%

11.6%

Cost of Goods Sold, Total

2,325

3,079.4

5,461.2

8,544.6

10,206.4

Gross Profit

1,658.7

2,533

4,828.9

6,724

6,827.9

Selling General & Admin Expenses, Total

444.4

605.9

1,000.6

1,432.5

1,789.4

Provision for Bad Debts

6.7

116.1

132.4

260

296.5

R&D Expenses

259.7

303.7

501.6

682.8

785.8

Other Operating Expenses

5

24.3

-1.5

23.5

Other Operating Expenses, Total

710.7

1,030.6

1,658.8

2,373.8

2,895.2

Operating Income

948

1,502.3

3,170.1

4,350.2

3,932.7

Interest Expense, Total

-19.6

-42.7

-39.2

-64.4

-158.5

Interest And Investment Income

75.8

80.9

58

115.8

219.2

Net Interest Expenses

56.1

38.1

18.8

51.4

60.7

Income (Loss) On Equity Invest.

-3.1

2.6

Currency Exchange Gains (Loss)

8.1

-91.3

-32.6

417.2

46.7

Other Non Operating Income (Expenses)

114

142.5

171.4

159.6

173.4

EBT, Excl. Unusual Items

1,123.1

1,594.3

3,327.7

4,978.3

4,213.5

Gain (Loss) On Sale Of Investments

3.5

371.4

665.4

379.4

13.8

Other Unusual Items

-53.6

EBT, Incl. Unusual Items

1,126.6

1,965.8

3,993.1

5,357.8

4,173.8

Income Tax Expense

116.3

273.1

484.5

807.9

603.2

Earnings From Continuing Operations

1,010.3

1,692.7

3,508.6

4,549.9

3,570.6

Minority Interest

3.5

-3.8

-120.1

-129.6

-170.9

Net Income

1,013.8

1,688.9

3,388.5

4,420.3

3,399.7

Net Income to Common Incl Extra Items

1,013.8

1,688.9

3,388.5

4,420.3

3,399.7

Net Income to Common Excl. Extra Items

1,013.8

1,688.9

3,388.5

4,420.3

3,399.7

Total Shares Outstanding

3,883.6

4,084.8

4,224.4

4,225.3

4,222.7

Weighted Avg. Shares Outstanding

3,717.1

3,953

4,173.7

4,172.7

4,163.5

Weighted Avg. Shares Outstanding Dil

3,997.1

4,209.2

4,421.8

4,375.9

4,348.9

EPS

0.3

0.4

0.8

1.1

0.8

EPS Diluted

0.3

0.4

0.8

1

0.8

EBITDA

1,141.3

1,771.2

3,622.3

5,068.8

4,928.2

Effective Tax Rate

10.3%

13.9%

12.1%

15.1%

14.5%